---
schema_version: "secwatch.filing_event.v1"
accession: "0001829126-25-000765"
form_type: "8-K"
ticker: "BGMS"
cik: "0001130166"
company_name: "Bio Green Med Solution, Inc."
filed_at: "2025-02-06T23:59:59+00:00"
generated_at: "2026-05-27T01:25:29.741573+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Cyclacel raises up to $33M via Lazar & Helena equity lines; stockholders approve reverse split and share increases

## Summary
- Lazar purchase agreement: up to $8M in Common Stock, exercisable by company until Sept 30, 2026, in $1M/$2M increments.
- Helena equity line: up to $25M over 36 months; initial commitment shares $125K; purchases at 95% of VWAP, min stock price $0.20.
- Amended Armistice exchange: $1.1M cash deferred to Q1 2025 filing; additional 100,000 shares issued subject to stockholder approval (received).
- Stockholders approved reverse stock split (1:4 to 1:16), authorized shares increase to 250M, and issuances to Lazar and Armistice.
- Company believes it has regained Nasdaq minimum stockholders' equity of $2.5M after these transactions and Cyclacel Ltd. deconsolidation.

## SEC filing metadata
- accession: 0001829126-25-000765
- form_type: 8-K
- ticker: BGMS
- cik: 0001130166
- company_name: Bio Green Med Solution, Inc.
- filed_at: 2025-02-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 5.07, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1130166/000182912625000765/0001829126-25-000765-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1130166/000182912625000765/cyclacel_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001829126-25-000765
- JSON: https://secwatch.observer/filing/0001829126-25-000765.json
- Plain text: https://secwatch.observer/filing/0001829126-25-000765.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.